CASI Pharmaceuticals, Inc. (CASI)

CASI Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	4.69	13.47	17.08	47.11	38.7	57.06
Short-Term Investments	-	2.62	13.69	4.23	9.87	9.31
Cash & Short-Term Investments	4.69	16.09	30.77	51.34	48.57	66.37
Cash Growth	-77.49%	-47.70%	-40.06%	5.69%	-26.82%	22.36%
Accounts Receivable	2.61	15.35	9.55	12.97	9.8	4.65
Other Receivables	-	-	0.59	-	-	-
Receivables	2.61	15.35	10.14	12.97	9.8	4.65
Inventory	2.61	5.25	15.88	6.14	1.91	1.36
Prepaid Expenses	2.01	2.89	2.56	2.98	1.69	1.65
Total Current Assets	11.92	39.58	59.34	73.42	61.97	74.03
Property, Plant & Equipment	9.95	11.36	11.63	13.23	21.82	10.76
Long-Term Investments	1.72	1.91	1.69	7.46	40.13	29.44
Other Intangible Assets	0.22	0.24	1.84	1.06	12.2	13.21
Other Long-Term Assets	0.66	0.59	0.77	1.06	2.18	0.3
Total Assets	24.46	53.67	75.27	96.23	138.3	127.73
Accounts Payable	0.56	2.72	4.44	3.29	2.22	3.26
Accrued Expenses	20.01	8.47	7.15	7.64	6.04	1.97
Short-Term Debt	-	-	-	-	-	1.29
Current Portion of Long-Term Debt	18.86	18.39	-	-	-	-
Current Portion of Leases	-	1.22	0.73	0.87	1.06	0.94
Current Income Taxes Payable	-	-	-	1.9	-	-
Current Unearned Revenue	-	2.47	2.54	2.62	0.06	-
Other Current Liabilities	-	3.18	1.87	0.69	3.81	0.52
Total Current Liabilities	39.42	36.45	16.73	17.01	13.19	7.98
Long-Term Debt	-	-	18.9	-	-	-
Long-Term Leases	-	2.54	1.62	0.48	1.11	0.97
Long-Term Unearned Revenue	-	-	-	-	2.83	2.35
Other Long-Term Liabilities	13.63	12.84	13.87	11.82	13.22	12.87
Total Liabilities	53.05	51.82	51.1	29.3	30.34	24.16
Common Stock	0	0	0	0	0	1.24
Additional Paid-In Capital	721.24	713.3	695.79	691.77	696.22	658.25
Retained Earnings	-735.09	-700.08	-660.82	-637.16	-605.64	-570.5
Treasury Stock	-9.6	-9.6	-9.6	-9.33	-8.03	-8.03
Comprehensive Income & Other	-5.14	-1.77	-1.2	-0.7	1.95	0.59
Total Common Equity	-28.59	1.85	24.17	44.57	84.5	81.54
Minority Interest	-	-	-	22.36	23.46	22.03
Shareholders' Equity	-28.59	1.85	24.17	66.93	107.96	103.57
Total Liabilities & Equity	24.46	53.67	75.27	96.23	138.3	127.73
Total Debt	18.86	22.14	21.24	1.34	2.17	3.2
Net Cash (Debt)	-14.17	-6.05	9.53	49.99	46.41	63.18
Net Cash Growth	-	-	-80.94%	7.73%	-26.55%	21.39%
Net Cash Per Share	-0.86	-0.39	0.71	3.66	3.41	5.72
Filing Date Shares Outstanding	20.55	15.49	12.99	13.32	13.66	13.98
Total Common Shares Outstanding	20.55	15.49	13.38	13.46	13.98	12.39
Working Capital	-27.51	3.12	42.62	56.42	48.78	66.05
Book Value Per Share	-1.39	0.12	1.81	3.31	6.04	6.58
Tangible Book Value	-28.82	1.61	22.33	43.51	72.3	68.33
Tangible Book Value Per Share	-1.40	0.10	1.67	3.23	5.17	5.51
Machinery	-	6.58	6.68	1.24	1.73	1.62
Construction In Progress	-	-	0.02	5.73	12.1	1.19
Leasehold Improvements	-	7	7.19	7.16	1.13	0.99

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q